ArticleNature2020
Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I.
2 registry-linked trialsOpen access · greenAbstract read
In one paragraph
Article in Nature, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 798 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
798citing papers in PubMed, 2 pooled it
96.9field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Multicenter, Open-label, ExploRatory Platform Trial to EValuate ImmunOtherapy Combinations With Chemotherapy for the Treatment of Patients With PreviousLy UnTreated MetastatIc Pancreatic AdenOcarciNoma (REVOLUTION)
NCT06328387 phase1 / phase2unknown statusnot on this mapstarted 2024, after this paper: background citation
Open, Controlled, Multicenter Phase I/II Clinical Study of Hydroxychloroquine in Combination With Antibody-drug Conjugate Versus Antibody-drug Conjugate for Advanced Breast Cancer.
Who cites it
798 citing papers in PubMed, 2 syntheses or guidelines pooled it, 1,167 citations in OpenAlex.
- From tumor microenvironment orchestrators to actionable targets: a systematic review of TAM-targeted therapies in triple-negative breast cancer.International journal of clinical oncology · 2026Pooled it
- Genome-Wide Meta-Analysis Identifies Five Single-Nucleotide Polymorphisms Associated With Both Vitiligo and Freckles in the Chinese Han Population.Journal of cosmetic dermatology · 2025Pooled it
- Transcriptomic and microenvironment characteristics of triple-negative breast cancer under three different neoadjuvant treatment regimens.Breast cancer research and treatment · 2025Trial
- Short-Course Preoperative Radiation Therapy for Rectal Cancer: Toward a Curative Radio-Immuno-Biological Approach?Advances in radiation oncology · 2026Article
- VCP-Regulated LMF2 Stabilizes the Cholesterol Biosynthesis Enzyme HMGCS1 to Drive Cancer Progression and Confer Capecitabine Resistance in Triple-Negative Breast Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Lysosomal metabolism in pancreatic cancer and its crosstalk with host physiology.Genes & development · 2026Review
- The pivotal role of SCD1 in digestive cancers: Bridging lipid metabolic reprogramming and programmed cell death (Review).International journal of oncology · 2026Review
- Organelle-Selective Autophagy in Cancer Immunotherapy: Mitophagy and Nucleophagy-Related Nuclear Quality Control as Regulators of Tumor-Immune Interactions.International journal of molecular sciences · 2026Review
- ULK1-dependent autophagy initiation promotes MHC-I degradation and immune evasion in HPV-positive head and neck cancer.Cancer immunology research · 2026Article
- Article
- Review
- IL-15 boosts mesothelin- and CD70-CAR NK cell potency in PDAC without added benefit from dual targeting.Molecular therapy. Oncology · 2026Article
- Drugging small-molecule compounds in autophagy-dependent cell death to overcome cancer therapy resistance.Apoptosis : an international journal on programmed cell death · 2026Review
- Multifunctional Nanovaccine-Radiotherapy Synergy Drives Anti-Tumor Immunity via Multi-Cascade Cell Death for Pancreatic Cancer Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Canonical and noncanonical autophagy in immunity.Immunity · 2026Review
- Re-expression of MHC-I to treat CNS cancers.Oncotarget · 2026Review
- PiggyBac-Engineered Membrane-Bound IL7 TILs Combined with Anti-PD-1 Antibody Demonstrates Efficacy in Recurrent Ovarian Cancer: A First-in-Human Phase I Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Autophagy modulation in cancer.Nature reviews. Drug discovery · 2026Review
- PGK1 epigenetically silences STING via DNMT1 and its knockdown synergizes with STING agonists in pancreatic cancer.Acta pharmacologica Sinica · 2026Article
- Antigen Spreading via Localized Administration Enhances Adoptive TCR-T Cell Therapy in Pancreatic Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
738 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
Authors and funding
19 authors at 5 institutions in 2 countries.
Keisuke Yamamoto *Department of Radiation Oncology, Perlmutter Cancer Center, New York University School of Medicine, New York, NY, USA.
Anthony Venida *Department of Anatomy, University of California, San Francisco, San Francisco, CA, USA.
Julian YanoDepartment of Anatomy, University of California, San Francisco, San Francisco, CA, USA.
Douglas E BiancurDepartment of Radiation Oncology, Perlmutter Cancer Center, New York University School of Medicine, New York, NY, USA.
Miwako KakiuchiColumbia Center for Translational Immunology, Columbia University College of Physicians and Surgeons, New York, NY, USA.
Suprit GuptaDepartment of Anatomy, University of California, San Francisco, San Francisco, CA, USA.
Albert S W SohnDepartment of Radiation Oncology, Perlmutter Cancer Center, New York University School of Medicine, New York, NY, USA.
Subhadip MukhopadhyayDepartment of Radiation Oncology, Perlmutter Cancer Center, New York University School of Medicine, New York, NY, USA.
Elaine Y LinDepartment of Radiation Oncology, Perlmutter Cancer Center, New York University School of Medicine, New York, NY, USA.
Seth J ParkerDepartment of Radiation Oncology, Perlmutter Cancer Center, New York University School of Medicine, New York, NY, USA.
Robert S BanhDepartment of Radiation Oncology, Perlmutter Cancer Center, New York University School of Medicine, New York, NY, USA.
Joao A PauloDepartment of Cell Biology, Harvard Medical School, Boston, MA, USA.
Kwun Wah WenDepartment of Pathology, University of California, San Francisco, San Francisco, CA, USA.
Jayanta DebnathDepartment of Pathology, University of California, San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-8745-4069
Grace E KimDepartment of Pathology, University of California, San Francisco, San Francisco, CA, USA.
Joseph D ManciasDivision of Radiation and Genome Stability, Department of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Douglas T FearonCold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA.
Rushika M PereraDepartment of Anatomy, University of California, San Francisco, San Francisco, CA, USA. rushika.perera@ucsf.edu.
Alec C KimmelmanDepartment of Radiation Oncology, Perlmutter Cancer Center, New York University School of Medicine, New York, NY, USA. alec.kimmelman@nyulangone.org.
New York University · USUniversity of California, San Francisco · USHarvard University · USColumbia University · USCornell University · US
Funding
Vaccine FacilityP30CA016087 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ADRIANA HEGUY · 1985 to 2026
$83.1MThe RAS and P13K Pathways in Pancreatic AdenocarcinomaP01CA117969 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DEPINHO, RONALD ANTHONY · 2006 to 2025
$41.7MResearch BaseP30DK063720 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KRUMMEL, MATTHEW F · 2003 to 2019
$21.8MTRAINING PROGRAM IN MOLECULAR ONCOLOGY &IMMUNOLOGYT32CA009161 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI CARROLL, WILLIAM L., LEVY, DAVID E · 1985 to 2020
$13.3MIdentifying Metabolic Dependencies of Pancreatic CancersR35CA232124 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI KIMMELMAN, ALEC · 2018 to 2024
$6.5MPREDOCTORAL TRAINING IN BIOMEDICAL SCIENCEST32GM008568 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ANSEL, KARL MARK · 1995 to 2019
$6.3MAutophagy in Adhesion and MetastasisR01CA126792 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Jayanta Debnath · 2009 to 2026
$5.3MNetwork organization of the human autophagy systemR01GM095567 · NIGMS · HARVARD MEDICAL SCHOOL · PI HARPER, JEFFREY W, KIMMELMAN, ALEC · 2011 to 2018
$3.0MInvestigating the Role of Autophagy in Pancreatic Cancer Radiation ResistanceR01CA157490 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI KIMMELMAN, ALEC · 2011 to 2018
$2.5MTracking tumor evolution through in vivo organelle profilingDP2CA216364 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PERERA, RUSHIKA MIRIAM · 2016 to 2016
$2.4MAdvancing Multiplexed Isobaric Tag-based Strategies for Proteome ProfilingR01GM132129 · NIGMS · HARVARD MEDICAL SCHOOL · PI PAULO, JOAO A · 2019 to 2023
$1.7MInvestigating a Novel Glutamine Metabolism Pathway in Pancreatic CancerR01CA188048 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI KIMMELMAN, ALEC · 2015 to 2018
$1.5MNCI NIH HHS DP2 CA216364NCI NIH HHS F99 CA245822NCI NIH HHS P01 CA117969NCI NIH HHS P30 CA016087NCI NIH HHS R01 CA126792NCI NIH HHS R01 CA157490NCI NIH HHS R01 CA188048NCI NIH HHS R35 CA232124NCI NIH HHS T32 CA009161NIDDK NIH HHS P30 DK063720NIGMS NIH HHS R01 GM095567NIGMS NIH HHS R01 GM132129NIGMS NIH HHS T32 GM008568
Abstract
Immune evasion is a major obstacle for cancer treatment. Common mechanisms of evasion include impaired antigen presentation caused by mutations or loss of heterozygosity of the major histocompatibility complex class I (MHC-I), which has been implicated in resistance to immune checkpoint blockade (ICB) therapy
Indexed as
AdenocarcinomaAnimalsAntigen PresentationAutophagyCarcinoma, Pancreatic DuctalCD8-Positive T-LymphocytesCell Cycle CheckpointsCell Line, TumorChloroquineFemaleHistocompatibility Antigens Class IHumansIntracellular Signaling Peptides and ProteinsLysosomesMaleMiceChloroquineHistocompatibility Antigens Class IIntracellular Signaling Peptides and ProteinsNBR1 protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT04787991ClinicalTrials.gov
NCT06328387ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.